Key Highlights
- ARK Invest liquidated 3,578 Meta (META) shares valued at approximately $2.1 million from three separate funds
- The firm offloaded 95,090 Roku (ROKU) shares representing roughly $9.1 million in total value across several ETFs
- ARK purchased 84,939 Tempus AI shares for approximately $4.1 million during Wednesday’s trading session
- Tempus AI has climbed to become the third-largest position in ARK Innovation ETF, comprising around 5% of total assets
- Meta (META) faced a court verdict in an addiction lawsuit while simultaneously announcing workforce reductions
On Wednesday, March 25, Cathie Wood’s ARK Invest executed strategic portfolio adjustments, divesting from Meta (META) and Roku (ROKU) while increasing exposure to healthcare artificial intelligence firm Tempus AI.
The investment firm offloaded 3,578 shares of Meta (META) distributed among three separate funds. Calculated using Wednesday’s closing market price, the transaction totaled approximately $2.1 million. Following this divestment, ARK Innovation ETF maintains a position of approximately 105,000 Meta shares, currently valued near $63 million, representing roughly 1% of total fund assets.
Meta experienced significant developments on the same trading day. A jury delivered a verdict declaring both Meta and Google’s YouTube platform negligent for operating services that caused harm to minors and adolescents in a groundbreaking social media addiction lawsuit. Both technology giants announced intentions to pursue appeals.
Meta simultaneously introduced a revised executive compensation structure aiming for a 500% stock appreciation and $9 trillion market capitalization target by 2031. The social media giant confirmed to Barron’s that workforce reductions affecting several hundred positions across sales, talent acquisition, and virtual reality departments were underway. Despite these significant announcements, Meta’s stock price concluded the session with a modest 0.3% gain.
ARK simultaneously divested 95,090 Roku (ROKU) shares spanning its ARKK, ARKW, and ARKF portfolios, generating approximately $9.1 million in proceeds. This transaction continued a selling pattern established the previous trading day on March 24.
Additional divestments executed Wednesday included 30,174 Teradyne shares valued at roughly $9.7 million, alongside 205,019 Bullish shares across three exchange-traded funds totaling about $7.7 million. ARK has maintained a consistent Bullish selling pattern throughout the preceding week.
Further portfolio reductions encompassed 62,393 Kratos Defense shares and 27,647 Natera shares, generating $4.8 million and $5.4 million respectively.
Tempus AI Emerges as Major ARK Holding
Regarding purchases, ARK’s primary allocation targeted Tempus AI. The investment firm acquired 84,939 shares through its ARKK and ARKG exchange-traded funds, deploying approximately $4.1 million in capital.
Tempus AI stock declined 4.2% during Wednesday’s session and has retreated 21% year-to-date in 2026. ARK’s acquisition appears strategically timed as a value entry point.
ARK Innovation ETF currently maintains approximately 6.3 million Tempus AI shares valued above $294 million. This position has elevated to the fund’s third-largest allocation, trailing only Tesla and Crispr Therapeutics, accounting for approximately 5% of total portfolio weight.
Strategic Portfolio Repositioning Continues
Wednesday’s transactions reflect ARK’s ongoing strategic rebalancing initiative. The firm has systematically reduced allocations to Roku, Teradyne, and Bullish across multiple consecutive trading sessions.
Concurrently, ARK has aggressively accumulated Tempus AI shares. The healthcare technology enterprise leverages artificial intelligence to advance medical data analytics and oncology treatment solutions.
Minor purchases completed during the session also encompassed positions in Archer Aviation, Beam Therapeutics, and additional portfolio companies.
The ARK Innovation ETF concluded Wednesday’s trading with a 1.3% advance.
